Calvillo-Argüelles O, et al. - In this study involving retrospectively identified consecutive women with HER2-positive breast cancer who received trastuzumab with or without anthracyclines, researchers investigated if statins could prevent trastuzumab-induced cardiotoxicity. They matched patients receiving statins before and during cancer treatment to two patients of the same age (± 2 years) and anthracycline exposure status but without statin treatment. The focus of this study was on final left ventricular ejection fraction. The investigators evaluated the link between statin exposure and cardiotoxicity (secondary outcome) by using a logistic regression model. Of 129 included patients (aged 62 ± 9 years), statins were given to 43 during cancer treatment. The median trastuzumab exposure time was 11.8 months. Anthracyclines administered to 72 patients (56%). Likeliness to have diabetes, hypertension, and coronary artery disease was more pronounced in patients treated with statins vs controls. Overall, a lower risk of cardiotoxicity was observed in association with concomitant use of statins in women with HER2-positive breast cancer receiving trastuzumab-based therapy with or without anthracyclines.